Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.542 estudios en Oncología (médica) (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors Rochester, Minn. The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors. The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood. Screening for High Frequency Malignant Disease Rochester, Minn., La Crosse, Wis., Eau Claire, Wis. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations. Cancer Distress Management Program for Liver and Biliary Cancer within a SPORE Rochester, Minn. The aim of this study is to develop a feasible, acceptable, and sustainable comprehensive cancer distress management program that is tailored to the unique needs of cancer patient survivors. A Study Evaluating the Safety and Effectiveness of Therapies in Patients with Metastatic Colorectal Cancer Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. The purpose of this study for the Inavo + Cetux Arm (A): To evaluate the effectiveness of Inavo + Cetux in PIK3CA-mutated colorectal cancer (CRC) with no detected RAS (KRAS, NRAS) or BRAFV600E mutations. The purpose of this study for the Inavo + Bev Arm (B_: To evaluate the effectiveness Inavo + Bev in PIK3CA-mutated, RAS (KRAS, NRAS)-mutated CRC. The purpose of this study for the Atezo+SY-5069 Arm (C): To evaluate the effectiveness of atezolizumab and SY-5609 treatment combination on patients with mCRC. The purpose of this study for the GDC-6036+cetuzimab+FOLFOX Arm (E): To evaluate the effectivenss of GDC-6036 plus cetuximab plus FOLFOX on patients with mCRC. The purpose of this study for the GDC-6036 plus cetuximab Arm (F): To evaluate the effectivenss of GDC-6036 plus cetuximab on patients with mCRC. The purpose of this study for the atezolizumab plus tiragolumab or atezolizumab plus tiragolumab and bevacizumab Arm (MSI-H): To evaluate the effectivenss of atezolizumab plus tiragolumab or atezolizumab plus tiragolumab and bevacizumab. ROF2181 Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. Currently, only a few international institutions use CIRT to treat pelvic bone sarcomas. Accordingly, data evaluating the potential differences in oncological outcomes, toxicities, and functional outcomes between CIRT and the more readily accessible local therapies of surgery and PT is scarce. For this reason, we propose conducting a prospective comparative effectiveness study evaluating functional outcomes, toxicities, and local control in patients with pelvic bone sarcomas treated with surgery, PT, and CIRT. TheraSphere With and Without Durvalumab and Tremelimumab for HCC Jacksonville, Fla. The objective of the ROWAN clinical study is to assess the the durability of local tumor control in Hepatocellular Carcinoma (HCC) patients who receive TheraSphere followed by durvalumab and tremelimumab, compared to those who receive TheraSphere treatment alone. Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the effectiveness of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma. Mayo Clinic Vestibular Schwannoma Quality of Life Index Assessment Rochester, Minn. The purpose of the study is to conduct cognitive testing of the recently published Mayo Clinic Vestibular Schwannoma Quality of Life (VSQOL) Index. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) Rochester, Minn. The purpose of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1). A Bio-bank for Patients with Inflammatory Bowel Disease Associated Neoplasia Rochester, Minn. The purpose of this study is to collect blood and stool samples to validate and improve the performance of stool and blood DNA markers for inflammatory bowel disease and colorectal neoplasia critical to the long-term goal of improving effectiveness of neoplasia detection in patients using non-invasive biomarkers to assist colonoscopy and radiographic screening. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 5151 Ir a página 5252 Ir a página 5353 Ir a página 5454 Ir a página 5555 SiguientePróxima página Solicite una consulta Conocimientos y categoríasInvestigación May 09, 2023 Comparte en: FacebookTwitter Mayo Clinic en Rochester, Minnesota, Mayo Clinic en Jacksonville, Florida y Mayo Clinic en Phoenix y Scottsdale, Arizona, han sido reconocidas entre los mejores hospitales oncológicos en el país durante el período 2023-2024 por U.S. News and World Report. Lee más sobre este gran honor. Oncología (médica)Página inicialdel departamentoSeccionesDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20180179 Centros y departamentos médicos Oncología (médica)